Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

1,662 public trials 323 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Completed

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

NCT02223052

Conditions
Acute Myeloid Leukemia, Adenocarcinoma, Adnexal Diseases, +106 more
Locations
  • Scottsdale Healthcare Research Institute Scottsdale, Arizona, United States
  • Mayo Clinic - Arizona Scottsdale, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • University of Iowa Iowa City, Iowa, United States
View Trial Details
Completed

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

NCT02322320

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Arizona Cancer Center Tucson, Arizona, United States
  • City of Hope National Medical Center Duarte, California, United States
  • University of California, San Diego Medical Center La Jolla, California, United States
  • Stanford Hospital and Clinics Stanford, California, United States
View all 42 locations
View Trial Details
Completed

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

NCT02636010

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hospital Germans Trias i Pujol Badalona, Spain
  • Hospital Clinic Barcelona, Spain
  • Hospital 12 de octubre Madrid, Spain
  • Hospital Ramón y Cajal Madrid, Spain
View Trial Details
Completed

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

NCT01660633

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Rush University Medical Center Chicago, Illinois, United States
  • University of Kansas Medical Center Fairway, Kansas, United States
  • University of Massachusetts Worcester, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details
Completed

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01497093

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details
Completed

Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse

NCT01087008

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hospital Universitari Germans Trias I Pujol Badalona, Spain
  • Hospital de la Santa Creu i Sant Pau Barcelona, Spain
  • Hospital del Mar Barcelona, Spain
  • Hospital Vall d'Hebrón Barcelona, Spain
View all 16 locations
View Trial Details
Completed

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

NCT01023308

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Novartis Investigative Site Phoenix, Arizona, United States
  • Novartis Investigative Site Anaheim, California, United States
  • Novartis Investigative Site Concord, California, United States
  • Novartis Investigative Site Los Angeles, California, United States
View all 210 locations
View Trial Details
Completed

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

NCT02902965

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Fakultní nemocnice Brno Brno, Czechia
  • Fakultní nemocnice Hradec Králové Nový Hradec Králové, Czechia
  • Fakultní nemocnice Ostrava Ostrava-Poruba, Czechia
  • Všeobecná fakultní nemocnice v Praha Prague, Czechia
View all 33 locations
View Trial Details
Completed

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

NCT01478581

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • SITE-13 La Jolla, California, United States
  • SITE-5 Baltimore, Maryland, United States
  • SITE-4 Boston, Massachusetts, United States
  • SITE-8 Ann Arbor, Michigan, United States
View Trial Details

Related conditions